Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jul;99(7):1396-1399.
doi: 10.1002/ajh.27302. Epub 2024 Apr 1.

A 10-year follow-up of high-dose ambroxol treatment combined with enzyme replacement therapy for neuropathic Gaucher disease

Soojin Hwang  1   2 , Hyunwoo Bae  1 , Ji-Hee Yoon  1 , Dohyung Kim  1 , Hyo-Sang Do  3 , Sun Hee Heo  3 , Soyoung Kim  3 , Han-Wook Yoo  4 , Majdolen Istaiti  5 , Ari Zimran  5 , Beom Hee Lee  1   2
Affiliations
Free article
Case Reports

A 10-year follow-up of high-dose ambroxol treatment combined with enzyme replacement therapy for neuropathic Gaucher disease

Soojin Hwang et al. Am J Hematol. 2024 Jul.
Free article

Abstract

High-dose ambroxol therapy combined with ERT in patients with neuropathic Gaucher disease.

PubMed Disclaimer

References

REFERENCES

    1. Grabowski GA, Zimran A, Ida H. Gaucher disease types 1 and 3: phenotypic characterization of large populations from the ICGG Gaucher registry. Am J Hematol. 2015;90(Suppl 1):S12‐S18. doi:10.1002/ajh.24063
    1. Castillon G, Chang SC, Moride Y. Global incidence and prevalence of Gaucher disease: a targeted literature review. J Clin Med. 2022;12(1):85. doi:10.3390/jcm12010085
    1. Kim YM, Choi JH, Kim GH, et al. The GBA p.G85E mutation in Korean patients with non‐neuronopathic Gaucher disease: founder and neuroprotective effects. Orphanet J Rare Dis. 2020;15(1):318. doi:10.1186/s13023‐020‐01597‐0
    1. Narita A, Shirai K, Itamura S, et al. Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study. Ann Clin Transl Neurol. 2016;3(3):200‐215. doi:10.1002/acn3.292
    1. Kim YM, Yum MS, Heo SH, et al. Pharmacologic properties of high‐dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy. J Med Genet. 2020;57(2):124‐131. doi:10.1136/jmedgenet‐2019‐106132